Yahoo Finance Today’s Research Reports on Neovasc, IntelliPharmaCeutics International, Nuvo Pharmaceuticals and Baylin Technologies
NEW YORK, NY / ACCESSWIRE / April 12, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Neovasc Inc.
https://rdinvesting.com/news/?ticker=NVCN.TO
IntelliPharmaCeutics International Inc.
https://rdinvesting.com/news/?ticker=IPCI.TO
Nuvo Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=NRI.TO
Baylin Technologies Inc.
https://rdinvesting.com/news/?ticker=BYL.TO
Neovasc's stock moved 7.14% lower Wednesday, to close the day at $0.07. The stock recorded a trading volume of 7,042,669 shares, which was above its three months average volume of 1,425,783 shares. In the last year, Neovasc's shares have traded in a range of 0.06 - 2.48. The stock is currently trading 97.38% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.28 is below its 200-day moving average of $1.03. Shares of the company are trading at a Price to Earnings ratio of 0.26. Shares of Neovasc have fallen approximately 90.67 percent year-to-date.
Access RDI's Neovasc Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NVCN.TO
On Wednesday, shares of IntelliPharmaCeutics International recorded a trading volume of 150 shares, which was below the three months average volume of 31,732 shares. The stock ended the day flat at 0.80. The share price has gained 17.65% from its 52 week low with a 52 week trading range of 0.68 - 3.73. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.80 is below its 200-day moving average of $1.03. Shares of IntelliPharmaCeutics International have fallen approximately 19.19 percent year-to-date.
Access RDI's IntelliPharmaCeutics International Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IPCI.TO
Nuvo Pharmaceuticals Inc.'s stock moved 5.80% lower Wednesday, to close the day at $3.25. The stock recorded a trading volume of 4,246 shares, which was below its three months average volume of 9,285 shares. In the last year, Nuvo Pharmaceuticals' shares have traded in a range of 3.03 - 5.49. The stock is currently trading 40.80% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $3.45 is below its 200-day moving average of $3.79. Shares of Nuvo Pharmaceuticals are trading at a Price to Earnings ratio of 11.48. Shares of Nuvo Pharmaceuticals have fallen approximately 12.16 percent year-to-date.
Access RDI's Nuvo Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=NRI.TO
On Wednesday, shares of Baylin Technologies recorded a trading volume of 9,309 shares, which was below the three months average volume of 41,020 shares. The stock ended the day 3.28% lower at 3.83. The share price has gained 104.81% from its 52 week low with a 52 week trading range of 1.87 - 4.12. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.77 is greater than its 200-day moving average of $3.06. Shares of Baylin Technologies have gained approximately 11.34 percent year-to-date.
Access RDI's Baylin Technologies Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BYL.TO
Our Actionable Research on Neovasc Inc. (TSX:NVCN.TO), IntelliPharmaCeutics International Inc. (TSX:IPCI.TO), Nuvo Pharmaceuticals Inc. (TSX:NRI.TO) and Baylin Technologies Inc. (TSX:BYL.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
